Fecal calprotectin tests are stool-based diagnostic tests used to identify inflammation in the gastrointestinal tract. They provide a quick, non-invasive way to detect inflammatory bowel disease (IBD) conditions such as Crohn’s disease and ulcerative colitis. With rising IBD prevalence worldwide due to environmental and lifestyle changes, the demand for effective diagnostic tools is growing.
The global Fecal Calprotectin Test Market is estimated to be valued at US$ 140.6 Mn in 2023 and is expected to exhibit a CAGR of 10.% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
The growth of the Fecal Calprotectin Test Market is primarily driven by the increasing prevalence of inflammatory bowel diseases (IBD) globally. Environmental and lifestyle changes have led to a significant rise in IBD cases over the past few decades. According to epidemiology studies, countries with traditionally low incidence rates such as Asia, South America, and Eastern Europe are now witnessing steep increases in IBD burden. Effective diagnostic tools are critical to manage the growing IBD patient pool worldwide. Fecal calprotectin, being a sensitive non-invasive marker of gut inflammation, plays an important role in screening and monitoring disease activity. Its ability to distinguish between inflammatory and non-inflammatory bowel conditions also makes it a preferred diagnostic method.
SWOT Analysis
Strength: Fecal calprotectin tests provide non-invasive means of evaluating inflammation in the gastrointestinal tract. It has high sensitivity and specificity for detecting intestinal inflammation.
Weakness: Fecal sampling can be unpleasant for patients. Results are not immediately available and require lab testing.
Opportunity: Rising prevalence of inflammatory bowel diseases like Crohn’s disease and ulcerative colitis is driving the need for effective diagnostic tools. Growing awareness about fecal calprotectin tests presents an opportunity.
Threats: Strict regulatory environment for in vitro diagnostic tests poses challenges. Alternative diagnostic methods can limit adoption.
Key Takeaways
The global Fecal Calprotectin Test Market Analysis is expected to witness high over the forecast period. North America currently dominates the market due to increasing inflammatory bowel disease prevalence in the US and Canada. Europe is the second largest market driven by rising research activities. Asia Pacific is expected to grow at the fastest pace with growing healthcare expenditures in China and India.
Key players operating in the fecal calprotectin test market are Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbexa Limited, Bioserv Diagnostics Gmbh, Epitope Diagnostics, Inc., LifeSpan BioSciences, Inc., RayBiotech, Inc., and ALPCO. Thermo Fisher Scientific and Roche respectively hold the largest market share due to their robust product portfolio and global presence. Other players are focused on developing novel tests and expansion strategies to gain market share.
The global fecal calprotectin test market size was valued at US$ 140.6 Mn in 2023 and is anticipated to reach US$ 307.4 Mn by 2030, expanding at a CAGR of 10% during the forecast period. Rising burden of inflammatory bowel diseases and growing diagnosis rates are expected to drive the demand for fecal calprotectin tests over the next few years.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. With an MBA in E-commerce, she has an expertise in SEO-optimized content that resonates with industry professionals.